BMRN Biomarin Pharmaceutical PE ratio, current and historical analysis
- Stocks
- Healthcare
- NASDAQ: BMRN
- PE Ratio
As of May 14, 2025, the Biomarin Pharmaceutical stock's PE ratio is 21.35. This results from the current EPS of $2.75 and stock price of $58.7. The P/E ratio has a decrease of 46% from the past four quarters average of 39.3.
BMRN PE ratio history
The PE ratio of Biomarin Pharmaceutical has averaged 176.84 over the last six years. The current PE ratio of 21.35 is 88% below the historical average. Over the past six years, BMRN's PE ratio was at its highest in the Sep 2021 quarter at 1,288.17, when the stock price was $77.29 and the EPS was $0.06. The lowest value was in the Sep 2020 quarter, when it reached 16.15 with a price of $76.08 and an EPS of $4.71.
Biomarin Pharmaceutical PE ratio by year
Maximum annual decrease: -73.04% in 2024
| Year | PE ratio | PE change | Price | EPS |
|---|---|---|---|---|
| 2024 | 29.21 | -73.04% | $65.73 | $2.25 |
| 2023 | 108.34 | -20.44% | $96.42 | $0.89 |
| 2022 | 136.17 | N/A | $103.49 | $0.76 |
| 2021 | N/A | N/A | $88.35 | -$0.35 |
| 2020 | 18.58 | N/A | $87.69 | $4.72 |
| 2019 | N/A | N/A | $84.55 | -$0.13 |
| 2018 | N/A | N/A | $85.15 | -$0.44 |
| 2017 | N/A | N/A | $89.17 | -$0.67 |
| 2016 | N/A | N/A | $82.84 | -$3.8 |
| 2015 | N/A | N/A | $104.76 | -$1.07 |
| 2014 | N/A | N/A | $90.4 | -$0.92 |
| 2013 | N/A | N/A | $70.35 | -$1.28 |
| 2012 | N/A | N/A | $49.2 | -$0.95 |
| 2011 | N/A | N/A | $34.38 | -$0.48 |
| 2010 | 13.47 | N/A | $26.93 | $2 |
Biomarin Pharmaceutical PE ratio by quarter (TTM)
| Year | PE ratio | PE change | Price | EPS |
|---|---|---|---|---|
| Mar 2025 | 25.71 | -11.98% | $70.69 | $2.75 |
| Dec 2024 | 29.21 | -29.36% | $65.73 | $2.25 |
| Sep 2024 | 41.35 | -32.2% | $70.29 | $1.7 |
| Jun 2024 | 60.99 | -23.89% | $82.33 | $1.35 |
| Mar 2024 | 80.13 | -26.04% | $87.34 | $1.09 |
| Dec 2023 | 108.34 | -5.72% | $96.42 | $0.89 |
| Sep 2023 | 114.91 | -31.06% | $88.48 | $0.77 |
| Jun 2023 | 166.69 | -36.57% | $86.68 | $0.52 |
| Mar 2023 | 262.81 | 93% | $97.24 | $0.37 |
| Dec 2022 | 136.17 | -27.72% | $103.49 | $0.76 |
| Sep 2022 | 188.38 | -34.08% | $84.77 | $0.45 |
| Jun 2022 | 285.76 | -22.17% | $82.87 | $0.29 |
| Mar 2022 | 367.14 | N/A | $77.1 | $0.21 |
| Dec 2021 | N/A | N/A | $88.35 | -$0.35 |
| Sep 2021 | 1,288.17 | 6,985.64% | $77.29 | $0.06 |
BMRN Price vs fair value
BMRN average PE ratio chart
BMRN's current P/E ratio is below the 3, 5 and 10-year averages.
BMRN PE vs peers
Compared to its peer stock CPRX, BMRN's PE ratio stands higher.
| Stock name | PE ratio | Market cap |
|---|---|---|
| CPRX Catalyst Pharmaceuticals Inc | 14.18 | $2.85B |
| BMRN Biomarin Pharmaceutical Inc | 21.35 | $11.26B |
| RARE Ultragenyx Pharmaceutical Inc | N/A | $3.28B |
| SGMO Sangamo Therapeutics Inc | N/A | $102.13M |
| FOLD Amicus Therapeutics Inc | N/A | $1.81B |
| ESPR Esperion Therapeutics Inc | N/A | $144.69M |
Frequently asked questions
What is Biomarin Pharmaceutical's PE ratio?
The price to earnings ratio for BMRN stock as of May 14, 2025, stands at 21.35.
What is the 3-year average PE ratio for Biomarin Pharmaceutical (BMRN)?
The 3-year average PE ratio for BMRN stock is 125.04.
What is the 5-year average PE ratio for Biomarin Pharmaceutical (BMRN)?
The 5-year average PE ratio for BMRN stock is 179.2.
What is the highest PE ratio for BMRN?
Over the last six years, the quarterly PE ratio reached a historic high of 1,288.17 in the Sep 2021 quarter.
How does the current PE ratio for BMRN compare to its historical average?
BMRN's price to earnings ratio is currently 88% below its 6-year historical average.
How is BMRN's PE ratio calculated (Biomarin Pharmaceutical PE ratio formula)?
To determine the PE ratio, divide the most recent stock price by the TTM earnings per share (EPS). As of today (May 14, 2025), Biomarin Pharmaceutical's stock price is $58.7. The earnings per share for the trailing twelve months (TTM) ending Mar 2025 is $2.75. Therefore, Biomarin Pharmaceutical's P/E ratio for today is 21.35. PE RATIO(21.35) = STOCK PRICE($58.7) / TTM EPS($2.75)
All PE ratio stats are based on quarterly TTM periods, unless otherwise specified.